84 results about "Spironolactone" patented technology

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

The invention discloses an acaricide composition containing spirodiclofen and etoxazole and application thereof. Spirodiclofen and etoxazole are used as active components of the acaricide composition, and the mass ratio of spirodiclofen to etoxazole is 30:1 to 1:30. According to the invention, a mutual synergy effect of the two active components of the acaricide composition is obtained, and application of the acaricide composition not only enables control efficiency to be improved, but also enables problems of resistance, drug effects, cost and the like caused by utilization of a single component to be overcome, providing a novel acaricide composition for guiding control of pest mites.

The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and/or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

The invention belongs to the field of pharmaceutical preparations, and relates to a pharmaceutical composition for improving in-vitro dissolution and liquidity of spironolactone and a preparation method of the pharmaceutical composition. The pharmaceutical composition is mainly characterized by being prepared from an indissolvable drug spironolactone and a carrier material, wherein the mass ratio of the drug to the carrier is 1:3-1:10, the pharmaceutical composition prepared through a hot-melt extrusion technique is solid dispersion, the spironolactone is dispersed into the carrier in a molecular or amorphous mode, and therefore the in-vitro dissolution of the spironolactone is significantly improved. After the spironolactone is smashed, the liquidity of the spironolactone is significantly improved, and the smashed spironolactone can be directly filled into capsules or directly subpackaged by serving as powder and granules or used by being mixed with other pharmaceutical auxiliary materials to prepare tablets. Compared with traditional methods such as the solvent method and the solvent-melt method, the adopted hot-melt extrusion technique has the advantages of being capable of not using an organic solvent, safe, free of pollution, stable in technology, capable of achieving continuous operation, easily achieving industrialized enlarged production and improving the liquidity without needing to add a flow aid and the like.

The present invention relates to medicine, and especially a kind of acne treating medicine and its preparation process. The acne treating medicine includes dephenhydramine, cimetidine, dexamethasone, metronidazole, spironolactone, salicylic acid and astragalus root in certain weight proportion as main ingredients, and has also the supplementary material including 50% concentration alcohol solution, aloe juice, glycerine and essence in certain proportion. Clinical application shows that the acne treating medicine has the advantages of high absorption, no blocking of pores, fast acting, high treating effect, etc.

Described methods and compositions for treating Meibomian Gland Disease (MGD) for normalizing gland secretions and improving symptoms of ocular surface diseases associated with MGD. The methods concern treatment of a patient with aldosterone antagonists, such as spironolactone or analogues of spironolactone. Spironolactone is desirably added in a novel treatment composition, preferably in the form of an aqueous solution, emulsion or suspension in small but effective concentrations and in a novel vehicle that adds to the increased solubility of what previously was known to be an insoluble active agent. Moreover, it is believed that the specific lower but effective concentrations of spironolactone, and/or the pluronic vehicle of the treatment composition, permits optimal expression of essential lipids and upregulation of genes that control lipid production necessary to a more normalized lipid component of the tear film for the treatment and/or the prevention of signs and/or symptoms of MGD.

The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to the stereoisomerically unpurified form of the compound. These optically active compounds can be useful for obtaining reduction in moderate essential hypertension and it the treatment of congestive heart failure in humans with minimized undesirable side effects such as gynecomastia, tender breast enlargement and menstrual irregularities in women, and loss of libido in men.

The invention discloses a spirolactone and hydrochlorothiazide liposome preparation which is prepared mainly from the following the ingredients in parts by weight: 1 part of spirolactone, 1 part of hydrochlorothiazide, 3-15 parts of egg phosphatidylcholine, 1-8 parts of cholesterol, and 0.5-5 parts of sodium glycyl-cholate. The invention further discloses a spirolactone and hydrochlorothiazide pharmaceutical composition solid preparation which is prepared by adding other excipient commonly used on pharmacy with the spirolactone and hydrochlorothiazide liposome preparation. The invention improves the product quality of the preparation and reduces the toxic and side effects.

The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids.

The invention discloses a compound spirolactone nanoemulsion drug. The nano drug is prepared from the following materials in mass percentage: 1%-15% of spirolactone, 15%-35% of surfactant, 5%-20% of cosurfactant, 5%-20% of oil, 0.5%-10% of hawthorn extract, 0.5%-10% of asarum extract and the balance of distilled water, wherein the sum of the mass percentages of the ingredients is 100%. According to the invention, after the spirolactone is prepared into nanoemulsion dosage form, the ability of penetrating blood brain barrier is obviously increased, the bioavailability of active compound is obviously improved, the half-life period of the drug is prolonged, and the administration times are reduced. The dissolving and penetrating abilities of the drug of the spirolactone are improved by the nanoemulsion, and the stability of the spirolactone is increased. The spirolactone nanoemulsion drug has obvious synergistic effect after being combined with aqueous extract of the hawthorn and asarum, and the curative effect of the drug is brought into full play.

The invention discloses a formyl thiourea bridged ferrocene-rhodamine B spironolactam multi-channel response receptor molecule and a synthesis method and application thereof. Combining ferrocene and rhodamine B spironolactam into a reactive photoactive acceptor molecule with formyl thiourea as a bridge structure, the specificity of Hg<2+> ions are used for promoting desulfurization and ring closing reaction to form a 1,3,4-oxadiazole heterocyclic ring, a rhodamine B spironolactone ring is simultaneously opened, the efficient and quick detection of selectivity of Hg<2+> ions in aqueous phases or cells based on electrochemistry, ultraviolet visibility, fluorescence spectroscopy and other technologies is realized, and broad application prospects are achieved.

The invention discloses an oil-in-water compound spironolactone nano emulsion medicine. The nano medicine is prepared from the following raw materials in percentage by mass: 1 to 5 percent of spironolactone, 15 to 30 percent of surfactant, 5 to 20 percent of cosurfactant, 5 to 20 percent of oil, 0.5 to 10 percent of hawthorn extract, 0.5 to 1.0 percent of wild ginger extract and the balance of distilled water, and the sum of the mass percentages of the components is 100 percent. After spironolactone is prepared into the nano emulsion preparation, so that the blood brain barrier penetrating capacity is improved obviously, the bioavailability of raw medicines is improved obviously, the half-life period of the medicine is prolonged, and the administration times are reduced; the nano emulsion improves the medicine dissolution and infiltration capacity of spironolactone and the stability of spironolactone; and after the hawthorn water extract and the wild ginger water extract are compounded, the nano emulsion medicine is obvious in synergistic effect, and is full in curative effect.

The invention discloses a pharmaceutical composition for treating edema diseases and cardiovascular and cerebrovascular diseases, in particular an oral drop pill preparation of the pharmaceutical composition with spironolactone as an active ingredient. The purpose of the present invention is to make up for the deficiencies of the prior art, to provide patients and medical workers with a medicine with large drug loading capacity, rapid drug release, rapid effect, high bioavailability, small toxic and side effects, low price and easy to take. Spironolactone drop pills. Take spironolactone as raw material, add surfactant polyethylene glycol and other substrates, heat until the pharmaceutical composition melt and/or emulsion and/or suspension containing spironolactone and substrate are obtained, put it into the dropping pill machine, drop into It is formed by shrinking in a condensing agent, taken out and wiped dry.

Disclosed is a compound microemulsion cream for treating acne which comprises the following constituents (by weight ratio): (1) stearic acid 8-10%, cetyl alcohol 2-4%, glyceryl monostearate 2-3%, fluid wax 2-8%, (2) triethanolamine 3-5%, 2-6% of at least one selected from glycerin, propylene glycol, 1,3-butylene glycol, 10% of ethyl-p-hydroxybenzoate alcoholic solution 1%, (3) 8-12% of at least one of n-propanol, n-butanol and n-pentanol, (4) medicaments including Azithromycin 0.25-0.75%, spironolactone 0.2-0.4%, vitamine-A acid 0.025-0.05%, and balancing purified water.